Stocktoria
Zivo Bioscience, Inc. ZIVO
OTC · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2000-10-06
Zivo Bioscience, Inc. (ZIVO) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2024 revenue was $157,220 at a -8513.4% net margin.
4/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Price from month-end closes (Yahoo) — for reference, not real-time.
Market cap$15M
Net margin-8513.4%
Revenue trend · last 10y · up
How it ranks in Manufacturing · percentile among 1906 companies
Piotroski Fstronger than 45%
Net marginstronger than 3%
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ZIVO | Zivo Bioscience, Inc. | 4/9 | — | — | — |
| VIVS | VivoSim Labs, INC. | 2/9 | — | — | — |
| ATYR | aTYR PHARMA INC | 1/9 | -19.49 | — | — |
| INMB | Inmune Bio, Inc. | 3/9 | — | — | — |
| ENTX | Entera Bio Ltd. | 2/9 | — | — | — |
| SNTI | Senti Biosciences Holdings, Inc. | 2/9 | — | — | — |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | 4/9 | -1.04 | — | — |
FAQ
Is ZIVO financially healthy?
Zivo Bioscience, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does ZIVO pay a dividend?
No, Zivo Bioscience, Inc. does not currently pay a dividend.
How profitable is ZIVO?
In FY2024, Zivo Bioscience, Inc. had a net margin of -8513.4%.
Source: SEC EDGAR filings · CIK 0001101026 · US · as of 2024-12-31. facts plus Stocktoria's own computed scores — not investment advice.